Russell Hausfeld is an investigative journalist and illustrator living in Cincinnati, Ohio. He has a Bachelor’s degree in Journalism and Religious Studies from the University of Cincinnati. His work with Psymposia has been cited in Vice, The Nation, Frontiers in Psychology, New York Magazine’s “Cover Story: Power Trip” podcast, the Daily Beast, the Outlaw Report, Harm Reduction Journal, and more.| Psymposia
Psymposia is a 501(c)(3) research non-profit with a mission to educate the public on psychedelic science and harm reduction.| Psymposia
Part 4 of The Psychedelic Syndicate reveals PSFC’s strategy to manufacture spiritual and moral authority through academic capture — even as some members align with far-right ideologies that deepen the very crises psychedelics are meant to heal. The post The Psychedelic Syndicate: Part 4 appeared first on Psymposia.| Psymposia
Part 3 of The Psychedelic Syndicate exposes how Silicon Valley's "move fast and break things" mentality infected psychedelic therapy, creating a culture where leaders rationalized patient harm as unavoidable for progress and ultimately embraced Trump administration officials who promised regulatory shortcuts. The post The Psychedelic Syndicate: Part 3 appeared first on Psymposia.| Psymposia
Part 2 of The Psychedelic Syndicate exposes the compromised foundation of PSFC's influence network — from the abuse scandals that undermined their preferred therapy model, to undisclosed ties with the sole FDA advisory committee member who voted unequivocally for MDMA approval. The post The Psychedelic Syndicate: Part 2 appeared first on Psymposia.| Psymposia
Part 1 of The Psychedelic Syndicate reveals how the Psychedelic Science Funders Collaborative (PSFC) — a wealthy network of Silicon Valley elites and Burning Man devotees — systematically captured| Psymposia
Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health. The post Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia appeared first on Psymposia.| Psymposia
In response to the The New York Times February 4 article, "How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy," Psymposia requested corrections to numerous errors and false accusation| Psymposia
Veterans deserve the highest quality treatment for PTSD. It’s unacceptable and dangerous to use veterans as guinea pigs for a big pharma profit grab without resolving safety and efficacy concerns.| Psymposia
The Church of Psilomethoxin now admits that its claims about psilomethoxin are solely based on faith. But how strong are the religious convictions of the Church?| Psymposia
Psymposia’s investigation into the Church of Psilomethoxin (CoP) turns to the Church’s claims that it’s currently “scientifically impossible” to test for psilomethoxin. Psychedelic chemist D| Psymposia
All the financial conflict disclosures from Psychedelics Science 2023 speakers, in one handy list.| Psymposia
The Church of Psilomethoxin claims it’s the victim of “psychedelic capitalism,” but almost everything it claims is wrong.| Psymposia
In order to present at Psychedelic Science 2023, speakers must agree to two out-of-the-ordinary requests about content exclusivity and MAPS’ reputation.| Psymposia
This is the first article in a series investigating the Church of Psilomethoxin (CoP), exploring the recent debate about the Church's sacrament and the people involved in promoting the Church and its| Psymposia
